CACécile Aubron

Cécile Aubron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cécile Aubron has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Red blood cell transfusion and acute kidney injury: an unproven association

    by Cécile Aubron, Elizabeth Moore, D. Jamie Cooper, Zoe McQuilten

    Red blood cell transfusion and acute kidney injury: an unproven association

  • Open Access

    Impact of gender on how intensive care medicine residents experience their medical studies and training and perceive their specialty: a national survey

    by Cécile Aubron, Cécile Plaud, Florian Reizine, Caroline Hauw-Berlemont, Charlotte Salmon Gandonnière, Laetitia Bodet-Contentin, Muriel Sarah Fartoukh, Mercedes Jourdain, Julien Le Marec, Fabienne Tamion, et al.

  • Open Access

    The Influence of Older Age on RBC Transfusion Decisions in ICU Patients

    by Caroline M. Schaap, Senta Jorinde Raasveld, Florian Reizine, Boillot Corentin, Jimmy Schenk, Sanne de Bruin, Merijn C. Reuland, Claudia van Den Oord, Andrew W. J. Flint, Tarikul Hamid, et al.

    Objectives: RBC transfusions are common in the ICU. Recent studies suggest that a restrictive transfusion policy is noninferior or superior to a liberal policy. However, few studies focus on the influence of age in transfusion. In elderly ICU patients, reduced physiologic reserves may shift the perceived risk-benefit balance of transfusion, potentially leading to different transfusion practices. This study examines whether transfusion practices in ICU patients differ across patient age. Design: This is a substudy of the International Point Prevalence Study of ICU Transfusion Practices (InPUT), a global, multicenter, prospective observational cohort study. Setting: ICUs from 233 centers across 30 countries. Data were collected from March 2019 to October 2022 in prespecified weeks. Patients: Adult ICU patients (≥ 18 yr) admitted during predefined study weeks. Patients were categorized by age (< 65, 65–75, 75–85, and > 85 yr). Interventions: None. Measurements and Main Results: A total of 3643 patients from 233 centers across 30 countries were included. Of these, 53% were younger than 65 years, 26% were 65–75 years, 17% were 75–85 years, and 4% were older than 85 years. RBC transfusion rates ranged from 23% to 26% across all age groups ( p = 0.91). Patients older than 85 years had higher stated hemoglobin thresholds (median, 10.0 g/dL) compared with younger patients (median, 8.0 g/dL; p < 0.001). “Age” and “improve general state” were more frequently cited as reasons for transfusion in patients older than 85 years. However, after adjustment, age was not associated with the probability of receiving an RBC transfusion. Conclusions: Different transfusion strategies are applied in patients older than 85 years old. These differences appear to be driven by age-related differences in physiology and diagnoses rather than motivated by older age itself.

  • Open Access

    Physiological determinants and the red blood cells transfusion decision-making process in non-bleeding critically ill patients: a comprehensive narrative review

    by Romain Tymen, Elaine Cavalcante dos Santos, Fabio Silvio Taccone, Cécile Aubron

    Purpose There is a willingness to move towards a more personalised medicine; however, the red blood cells’ (RBC) transfusion decision-making process remains a one-size-fits-all practice in most non-bleeding critically ill patients. This narrative review describes the limitations of a transfusion decision-making process based only on haemoglobin (Hb) threshold and the potential physiological triggers of RBC transfusion with the clinical evidence investigating their implementation in routine. Results Hb does not reflect tissue oxygenation and anaemia tolerance, and applying the same Hb threshold throughout the ICU stay neither prevents unnecessary transfusion nor insufficient transfusion. Central venous oxygen saturation (ScvO2) and oxygen extraction ratio (O2ER) are accessible at the bedside and display significant changes after RBC transfusion when in abnormal ranges. Although they have been prospectively investigated in the transfusion decision process, there is a need for more evidence to definitely implement them in routine. The arterial–venous difference in oxygen (A–VO2diff) might be another useful bedside RBC transfusion trigger. Microcirculatory markers are also promising candidates for physiological determinants for RBC transfusion. Conclusions There is a need for additional determinants in the RBC transfusion decision process to offset the limitations of RBC transfusion based only on Hb level in non-bleeding critically ill patients. A multimodal strategy, including comorbidities, underlying diseases, clinical signs, ECG changes, biochemical markers, and microcirculatory assessment, may optimise transfusion timing and avoid unnecessary red blood cell administration. However, further research is warranted to determine the potential benefit of integrating tissue oxygenation and microcirculatory parameters in the transfusion decision-making process.


  • Open Access

    Multinational transfusion practices and outcomes in haematology patients admitted to the intensive care unit

    by Caroline M Schaap, Laurens A Oomen, Senta Jorinde Raasveld, Jimmy Schenk, Sanne de Bruin, Merijn C Reuland, Claudia van Den Oord, Jan Bakker, Maurizio Cecconi, Aarne Feldheiser, et al.

    Background and Objectives: The number of critically ill patients with haematological conditions is increasing, yet transfusion practices in this population remain poorly defined. This study aimed to compare transfusion strategies in critically ill patients with versus without haematological conditions. Study Design and Methods: This international, prospective observational substudy of the International Point Prevalence Study of Intensive Care Unit [ICU] Transfusion Practices (InPUT) evaluated transfusion use in ICU patients with and without haematological conditions, including benign or malignant diseases or a history of stem cell transplantation. Outcomes included use of red blood cells (RBCs), platelets, plasma, haemostatic interventions, transfusion indications and thresholds. Results: Of 3643 ICU patients, 131 (3.6%) had a haematological condition. These patients were more likely to receive RBC (odds ratio [OR] 1.58, 95% confidence interval [CI] 1.09–2.29) and platelet transfusions (OR 8.32, 95% CI 5.09–13.6), primarily due to low haemoglobin rather than physiological triggers. Platelet thresholds were lower (median 23 × 10 9 /L vs. 64 × 10 9 /L) compared to non‐haematology patients. Both platelet and plasma transfusions were more frequently administered prophylactically rather than for active bleeding. Haemostatic interventions were more often used in haematology patients, at higher doses and typically without viscoelastic testing. Transfused haematology patients had higher 28‐day mortality and longer ICU stays. Conclusion: ICU patients with haematological conditions receive transfusions differently, particularly regarding platelet and plasma use. These findings underscore the need for prospective studies to define optimal transfusion thresholds in this growing and vulnerable patient population, although the study's limited sample size and lack of diagnostic granularity may affect interpretation.


  • Open Access

    Platelet Transfusion Practices in the ICU: A Prospective Multicenter Cohort Study

    by Stefan F van Wonderen, Senta Jorinde Raasveld, Andrew W J Flint, Jimmy Schenk, Claudia van Den Oord, Merijn C Reuland, Sanne de Bruin, Jan Bakker, Maurizio Cecconi, Aarne Feldheiser, et al.

    Objective: There is a lack of comprehensive international data regarding platelet transfusion practices in the ICU. This study aimed to evaluate the current occurrence rate of platelet transfusion in the ICU and provide an overview of platelet transfusion practices including indications for a platelet transfusion, thresholds, (non-)adherence and geo-economic region variations. Design: International prospective cohort study. Setting: Two hundred thirty-three centers in 30 countries worldwide. Patients: All patients 18 years old and older, admitted to the ICU during a single study week, selected by each site from one of the 16 predefined weeks (March 2019 to October 2022), were included. Interventions: None. Measurements and Main Results: Of the 3643 patients, 208 (6%) received a platelet transfusion during their ICU stay and main indications consisted of active bleeding (42%, n = 187/443), prophylaxis (33%, n = 144/443) or an upcoming procedure (12%, n = 51/443). The median platelet count before transfusion was 44 × 10 9 /L (interquartile range [IQR], 20–78) with variation by indication, including a higher median of 60 × 10 9 /L (IQR 31–93) during active bleeding. A threshold for transfusion was stated in 51% ( n = 224/443) of the events, with a median threshold platelet count of 50 × 10 9 /L (IQR, 40–100). The advised threshold was not adhered to in 16% ( n = 36/224) of cases, with the majority having active bleeding as indication. Contrasts in transfusion practices were observed across different geo-economic regions. Platelet transfusions were administered to 6% ( n = 156/2520) of patients in high-income countries, 5% ( n = 52/1069) of patients in upper-middle-income countries and in none from lower-middle-income countries ( n = 0/54). Non-adherence was higher in the high-income countries (23%, n = 34/149) than upper-middle-income countries (3%, n = 2/75). Conclusions: Platelet transfusions were administered to a small proportion of critically ill patients, and were given to treat active bleeding or as prophylaxis in the majority of cases. Occurence rate, indication and threshold adherence for platelet transfusion widely varied between geo-economic regions.


  • The impact of red blood cells storage duration on the development of acute kidney injury: A secondary analysis of the TRANSFUSE multicenter randomized controlled trial

    by Cécile Aubron, Elizabeth M. Moore, Bridget Ady, Eldho Paul, Maija Kaukonen, Lynne Murray, Jonathan Barrett, Matthew Bailey, Timothy Bowles, Sean Kelly, et al.

    Background: Red blood cell (RBC) transfusion is associated with an increased risk of acute kidney injury (AKI). The extent to which RBC storage affects this association is unclear. We aimed to evaluate the association between storage duration and the occurrence or worsening of any degree of AKI in critically ill patients.Study Design and Methods: In this pre‐planned sub‐study of the Standard Issue Transfusion versus Fresher Red‐Cell Use in Intensive Care (TRANSFUSE) trial, which compared mortality of critically ill patients receiving either the freshest available allogenic RBC unit or standard availability RBC, patients hospitalized in one of the 31 participating sites and who did not have Stage 3 AKI according to the Kidney Disease Improving Global Outcomes (KDIGO) classification were eligible. The primary outcome was the cumulative proportion of patients who developed any degree of new AKI.Results: A total of 899 patients were included. The mean (SD) RBC storage duration was 22.4 (7.4) versus 11.9 (5.4) days in the standard issue RBC and short‐storage RBC groups, respectively (p < 0.01). The percentage of patients who developed any stage of new AKI was similar between groups (24.8% in the standard issue RBC group versus 26.1% in the short‐storage RBC group; p = 0.66) (Relative Risk 0.95, [95% confidence intervals 0.76–1.19]). There was no difference in secondary outcomes.Discussion: In this pre‐planned sub‐study of the TRANSFUSE trial, compared with using standard issue RBC, the transfusion of the freshest available RBC was not associated with a decrease in AKI.


  • PROACTIVE SCREENING ALGORITHM FOR EARLY-ONSET PNEUMONIA IN PATIENTS WITH OUT-OF-HOSPITAL CARDIAC ARREST: A BEFORE-AFTER IMPLEMENTATION STUDY

    by Pauline Lemée, Xavier Chapalain, Pierre Bailly, Rosemary L. Sparrow, Vanessa Jean-Michel, Gwenael Prat, Anne Renault, Jean-Marie Tonnelier, Cécile Aubron

    Introduction: Early-onset pneumonia (EOP) occurs in around 50% of critically ill patients with out-of-hospital cardiac arrest (OHCA) and is associated with increased morbidity. Prompt diagnosis of EOP in these patients is difficult because of targeted temperature management and the postcardiac arrest syndrome. We hypothesized that an algorithm for proactive screening of EOP would improve patient outcomes. Methods: We conducted a single-center observational study comparing the outcomes of mechanically ventilated adult patients with OHCA, before (study period 1) and after (study period 2) implementation of an algorithm for proactive diagnosis of EOP, including an early distal pulmonary specimen. An inverse probability treatment weighted multivariable regression was performed to identify independent parameters associated with duration of mechanical ventilation. A subgroup analysis was conducted in patients alive on day 5 after intensive care unit admission. Results: Over the 4-year study period, 190 patients (99 and 91 for study periods 1 and 2, respectively) were enrolled. The overall incidence of EOP was 57.4% and was similar between both study periods. Although there was no difference in the time interval to antibiotic initiation, study period 2 was independently associated with higher SpO2/FiO2 ratios on days 3 and 4. We also observed a decrease in mechanical ventilation time in study period 2 (4.5 [1–11.3] vs. 3 [2–5.8] days; P = 0.07), and this reached statistical significance in the subgroup analysis of patients alive at day 5 (10 [5–17] vs. 5 [3–9] days, P = 0.01). Conclusion: In critically ill patients with OHCA, proactive diagnosis of EOP was not associated with a significant change in the time to antibiotic initiation. Further research is warranted to better define optimal diagnosis and management of EOP in this setting.

  • Open Access

    Anti-Factor-Xa and Activated Partial Thromboplastin Time Concordance and Outcomes in Adults Undergoing Extracorporeal Membrane Oxygenation: A Secondary Analysis of the Pilot Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation Randomized Trial

    by Cécile Aubron, Xavier Chapalain, Michael Bailey, Jasmin Board, Heidi RN Buhr, Bruce Mbbs Cartwright, Mark Dennis, Carol PhD Hodgson, Paul MBChB Forrest, David MBBS McIlroy, et al.

    OBJECTIVES: To determine the concordance between activated partial thromboplastin time (aPTT) and anti-factor-Xa (anti-Xa) in adults undergoing extracorporeal membrane oxygenation (ECMO) and to identify the factors associated with discordant paired aPTT/anti-Xa. DESIGN: Pre-planned secondary analysis of the Low-Dose Heparin in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation pilot randomized unblinded, parallel-group controlled trial. SETTING: Two ICUs in two university hospitals. PATIENTS: Thirty-two critically ill patients who underwent ECMO and who had at least one paired aPTT and anti-Xa assay performed at the same time. INTERVENTIONS: We analyzed the concordance between aPTT and anti-Xa and identified factors associated with discordant paired aPTT/anti-Xa based on their respective therapeutic ranges. We also compared biological parameters between heparin resistance episode and no heparin resistance. MEASUREMENTS AND MAIN RESULTS: Of the 32 patients who were included in this study, 24 (75%) had at least one discordant paired aPTT/anti-Xa. Of the 581 paired aPTT/anti-Xa that were analyzed, 202 were discordant. The aPTT was relatively lower than anti-Xa in 66 cases (32.7%) or relatively higher than anti-Xa in 136 cases (67.3%). Thirty-three heparin resistance episodes were identified in six patients (19%). CONCLUSIONS: In these critically ill patients undergoing ECMO, one third of paired aPTT/anti-Xa measures was discordant. Coagulopathy and heparin resistance might be the reasons for discordance. Our results support the potential importance of routinely monitoring both tests in this setting.